Grants for Special district governments - Health

This funding opportunity supports researchers investigating new biological, environmental, and social factors contributing to liver cancer in the U.S., particularly in relation to established risk factors and health disparities.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites U01 cooperative agreement applications for Physical Sciences-Oncology Network (PS-ON). The goal of the PS-ON is to foster the convergence of physical sciences approaches and perspectives with cancer research to advance our understanding of cancer biology and oncology by forming transdisciplinary teams of physical scientists and cancer biologists/physician scientists. Examples of physical scientists may include engineers, physicists, mathematicians, chemists, and computer scientists. The research projects funded through this FOA, individually and as a collaborative Network along with other funded research projects, will support transdisciplinary research that: (1) drives a physical sciences perspective within the cancer research community; (2) facilitates team science and field convergence at the intersection of physical sciences and cancer research; and (3) collectively tests physical sciences-based experimental and theoretical concepts of cancer and promotes innovative solutions to address outstanding questions in cancer research.

The purpose of this Notice of Funding Opportunity (NOFO) is to support milestone-driven projects focused on developing and utilizing novel predictive models, assays, tools, and/or platforms based on penetration and efflux of small molecules to facilitate therapeutic discovery for select Gram-negative bacterial pathogens: carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacteriaceae (CRE), and multidrug-resistant Pseudomonas aeruginosa. A number of Gram-negative bacterial pathogens are associated with the alarming increase in rates of drug resistance in healthcare and community settings. This group includes carbapenem-resistant Acinetobacter , carbapenem-resistant Enterobacterales (CRE), and MDR Pseudomonas aeruginosa that have been designated as “urgent” or “serious” threats in a recent report by the Centers for Disease Control and Prevention (CDC). A significant threat arises from the lack of effective therapeutic options available to treat some of these infections and is exacerbated by the scarcity of novel compounds effective against antimicrobial resistant (AR) and multidrug-resistant (MDR) Gram-negative bacteria in the discovery and development pipeline. In recent years, several public forums (including NIAID-sponsored workshops) identified the lack of understanding of the principles that govern compound penetration into, and efflux out of, Gram-negative bacteria as a key bottleneck for the rational discovery of novel lead therapeutic compounds. The paucity of suitable assays/tools/models to inform structure-activity relationships and guide optimization of whole cell penetration (and efflux avoidance) is reflected in the failure of medicinal chemistry efforts to advance novel chemical classes of compounds with Gram-negative activity. As more Gram-negative bacteria become resistant to antimicrobials and therapeutic options become limited or nonexistent, it becomes imperative to understand and rationalize the principles that allow molecules to penetrate Gram-negative bacteria, while avoiding efflux and overt toxicity toward eukaryotic cells. Therefore, developing new assays, tools, and models is paramount for overcoming this key bottleneck and facilitating the development of novel compounds targeting Gram-negative pathogens. Research Objectives and Scope The objective of this NOFO is to support milestone-driven projects focused on developing and utilizing novel predictive models, assays, tools, and/or platforms aimed at gaining a better understanding of the rules and compound properties that govern the penetration and efflux of drug-like small molecules into Gram-negative bacterial pathogens. This NOFO also supports the preclinical development of novel Gram-negative antibacterial therapeutics based on the tools and models hereby developed. Applications must focus on one or more of the following Gram-negative bacterial pathogens: carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales (CRE), and/or MDR Pseudomonas aeruginosa. Projects should complete assay/tool/model development prior to the end of the third year of the project period and initiate discovery activities to demonstrate its utility in supporting a corresponding medicinal chemistry program to generate a lead chemical series with demonstrated activity against one or more targeted Gram-negative bacteria. This NOFO will also support subsequent preclinical development of a promising lead antibacterial. Given the complex challenges of this research, this initiative encourages applications from multi-disciplinary teams composed of relevant experts in areas such as bacterial physiology, microbiology, bacterial membrane biology, medicinal chemistry, pharmacology, computation, and specialized technologies (microscopy, spectroscopy, electrophysiology, machine learning, etc.), as appropriate. Collaboration with, and utilization of, the NIAID Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB), is recommended for completion of project relevant medicinal chemistry tasks. Close collaboration between academic and industry partners is highly encouraged to optimally combine innovative basic science with drug discovery expertise and proper access to compound libraries more typically available from industry. Examples of assay and model development activities include, but are not limited to: Quantitative cellular (or model system) assays to measure drug penetration and efflux, independent from standard minimum inhibitory concentration (MIC) testing; Innovative quantitative assays to measure drug concentrations in the bacterial cytoplasm and/or periplasmic space; Innovative technologies for dissecting and assessment of the kinetics of drug penetration and efflux from bacteria; and Computational algorithms for describing/predicting physical-chemical properties/guidelines needed by small molecules for optimal Gram-negative penetration and efflux avoidance. Applicants should demonstrate the utility of the developed tools and/or assays to predict and measure potency of candidate therapeutics against Gram-negative targets through one or more approaches. For example, using the developed models and/or assays to guide a medicinal chemistry campaign aimed at producing a novel chemical series with Gram-negative activity; screening existing libraries using the computational algorithms developed as a tool to find compounds with Gram-negative activity; or profiling existing libraries of compounds with known Gram-negative activity. Applications including the following will be considered non-responsive and will not be reviewed: Projects that do not focus on at least one select Gram-negative pathogen (carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales, or MDR Pseudomonas aeruginosa); Projects focused only on Gram-positive bacteria or Mycobacterium tuberculosis; Projects that do not focus on penetration and efflux of small molecules; Applications not containing a Milestone and Timeline attachment; Applications proposing Clinical trials; and Research on HIV/AIDS.

This funding opportunity supports researchers in developing innovative animal models and biological tools to advance the understanding of Down syndrome and its related health conditions.

This funding opportunity supports innovative research projects that explore how climate change affects cancer risks, treatment, and survivorship, with a focus on developing solutions to mitigate these impacts and address health inequities.

The "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" grant aims to fund exploratory research projects that further develop and validate innovative technologies for analyzing molecular and cellular aspects of cancer, with the goal of improving cancer research, detection, diagnosis, treatment, and understanding of health disparities.

This grant provides funding for researchers to investigate the biological mechanisms behind adverse effects related to anti-beta-amyloid immunotherapy in Alzheimer's disease, with the goal of developing strategies to protect the blood-brain barrier and improve treatment safety.

This funding opportunity supports U.S.-based organizations in developing and testing effective cancer interventions that improve health outcomes for diverse populations across the entire cancer control continuum, particularly in under-resourced communities.

The purpose of this NOFO is to support projects to test prospective multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities. These research projects will be part of the Multi-Sectoral Preventive Interventions (MSPI) Research Network, which will also include a Coordinating Center (NOFO xxx). Funded under a cooperative agreement, projects participating in the MSPI Research Network will collaborate to share approaches, methods, and data, working closely with NIH Institutes, Offices and Centers. Applicants applying to this NOFO are encouraged to review the Coordinating Center NOFO to fully understand the MSPI Research Network structure and activities. This NOFO solicits bi-phasic research projects proposed in UG3/UH3 Phased Innovation Awards Cooperative Agreement applications. Funding for the UG3 phase (phase I) will be used to demonstrate sufficient preparation, feasibility and capacity to meet foundational milestone targets specific to the work proposed. A UG3 project that meets its milestones will be administratively considered by NIH and prioritized for transition to the UH3 award (phase II). Applicants responding to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases.

This funding opportunity supports researchers at various institutions to conduct basic experimental studies involving human participants, aimed at advancing our understanding of fundamental biological and behavioral processes.

This program provides funding to various organizations for research projects that improve workplace safety and health by identifying and reducing occupational hazards.

The "Effectiveness of School-Based Health Centers to Advance Health Equity" grant aims to fund research into how school-based health centers can effectively address the health needs of underserved school-aged children, particularly in managing and preventing chronic illnesses and understanding how these centers can improve health outcomes for at-risk groups such as immigrant youth and those in rural areas.

This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states.

This funding opportunity provides financial support for new and at-risk researchers from diverse backgrounds to conduct independent scientific studies, particularly in areas addressing health disparities and underrepresented populations.

This funding opportunity supports nonprofit organizations and government entities in Philadelphia to plant and care for at least 35,000 trees by 2035, focusing on community engagement and environmental equity.

This funding opportunity supports researchers and institutions in conducting early-phase clinical trials for innovative cancer treatments and diagnostic tools to improve patient care and address unmet needs in cancer research.

This funding opportunity provides financial support to current AHRQ grant holders to recruit and retain diverse students and early-career researchers in health services research, while also accommodating PIs with disabilities.

This funding opportunity supports clinician-investigators transitioning from residency to early career faculty roles, providing resources for research training and professional development in various health-related fields.

The State of Arizona, USDA Forest Service and DOI Bureau of Land Management are expected to provide funding assistance to the Arizona Department of Forestry and Fire Management for fire prevention, critical infrastructure protection and forest and watershed restoration through reduction of hazardous vegetation from state, federal, tribal and private lands in Arizona. Total funding of approximately $3 million will be made available through sub-awards (grants) from DFFM on a reimbursement basis and awarded through a competitive process with emphasis on community protection and forest health. Multiple awards not exceeding $500,000 are expected. Organizations may submit more than one project application, but total funding may be limited to $500,000. Priority will be given to projects that support private industry and/or Arizona’s wood products industry. Priority will be given to projects that have not received prior treatments. Financial Notes: Total funding of approximately $3 million will be made available through sub-awards (grants) from the Arizona Department of Forestry and Fire Management on a reimbursement basis and awarded through a competitive process with emphasis on community protection and forest health. Awards will be limited to a minimum of $60,000 and maximum of $500,000 per project. Depending on total available funding, some projects may be offered only partial funding. All projects will require a 10% - 30% match contribution (ie: 90% Grant + 10% Match = 100% Project Total). Match source must be identified in the project application. Larger requests will require larger match contributions.  Priority will be given to projects that support private industry and/or Arizona’s wood products industry. Priority will be given to projects that have not received prior treatments. Proposals not meeting minimum match requirements will impact the overall score. Funds will be dispersed to recipients on a reimbursement basis after they incur cost and report accomplishments and expenses to the Arizona Department of Forestry and Fire Management. For more information, please refer to the Request for Applications_NOFO form.

This funding opportunity provides financial support to state and local governments, nonprofits, and other organizations to improve vaccine access and confidence among Medicaid beneficiaries across the United States.